Salarius Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Salarius Pharmaceuticals Director Arnold C. Hanish sold a total of 27 common shares at $0.6397 per share on December 30, 2025, under a Rule 10b5-1 plan.
Salarius Pharmaceuticals Director Arnold C. Hanish acquired 5,000 shares of common stock at a weighted average price of $0.7481, increasing his indirect beneficial ownership.
Form 4: Salarius CFO Buys 20,000 Shares
Salarius Pharmaceuticals' Executive VP Finance and CFO, Mark J. Rosenblum, purchased 20,000 shares of common stock, signaling confidence in the company.
David J. Arthur, CEO of Salarius Pharmaceuticals, acquired 20,500 stock options on April 11, 2024.